

CURRICULUM VITAE

Thomas Wayne Mieras M.D.

8401 Datapoint, Suite 401
San Antonio, Texas 78229

7940 Floyd Curl Dr., Suite 1050
San Antonio, TX 78229

WORK TELEPHONE:

(210) – 949-0122 or 949-2200
(210) – 949-0181
E-mail – sapdmmieras@sbcglobal.net

BIRTH DATE:

October 23, 1955

PLACE OF BIRTH:

Tacoma, Washington

CITIZENSHIP:

United States of America

RESIDENCE:

6506 Pemcliff
San Antonio, TX 78240-2555

BOARD CERTIFICATION:

American Board of Internal Medicine
September 25, 1991
Certificate #137610

MEDICAL LICENSE:

Texas -- 1988 to present
H-4555

DEA REGISTRATION:

BM 2055134 -- current

TEXAS DPS REGISTRATION:

P0073298 -- current

EDUCATION:

1983 - 1987	Doctor of Medicine University of Texas Health Science Center at San Antonio School of Medicine
1980 - 1983	Texas A&M University No degree (accepted to medical school after three years of undergraduate education) College of Science College Station, TX
1970 - 1973	Killeen High School Killeen, TX

POSTGRADUATE TRAINING:


1987 - 1990	Internship and Residency, Internal Medicine University of Texas Health Science Center at San Antonio, Affiliated Hospitals
-------------	--

CLINICAL EXPERIENCE:

1990 - 1991	Chief Medical Resident Department of Internal Medicine
-------------	---

Thomas Wayne Mieras, M.D.
Revised 10/9/2007

Page 1

 10/9/07

University of Texas Health Science Center at San Antonio

1990 Instructor
Dental Residency Physical Diagnosis
University of Texas Health Science Center at San Antonio

1991 - 1999 Instructor
Physical Diagnosis, 2nd year Medical Students
University of Texas Health Science Center at San Antonio

1990 Instructor
1992 - 1995 Physical Diagnosis, 1st year Medical Students
University of Texas Health Science Center at San Antonio

1992 Internal Medicine Physician
San Antonio Force
Arena Football Team

1999 Community Based Teaching Award
American College of Physicians

1996 American College of Physicians
Preceptorship Award
Community Based Teaching Project

7/91 - 12/97 Diagnostic Clinic of San Antonio
Private practice, Internal Medicine
Group practice

1/1998 - present San Antonio Preventive & Diagnostic Medicine
Private practice, Internal Medicine
Group practice

ACADEMIC APPOINTMENTS:

1990 - 1991 Instructor of Medicine
Department of Internal Medicine
University of Texas Health Science Center at San Antonio

1991 - present Clinical Associate Professor of Medicine
Department of Internal Medicine
University of Texas Health Science Center at San Antonio

WORK EXPERIENCE:

1983 - 1987 Coordinator
Intramural Volleyball
University of Texas Health Science Center at San Antonio

1972 - 1980 McDonald's Restaurant
1978 - 1980 Manager
Killeen, TX

RESEARCH AFFILIATION:

2003 – Present Sub-Investigator/Principal Investigator
Clinical Trials of Texas, Inc.
San Antonio, TX

AWARDS AND HONORS:

1980 - 1983 Deans Honor Roll, three semesters
Texas A&M University

1980 - 1981 Texas A&M University
Phi Eta Sigma Honor Society
-- Treasurer
National Convention Delegate -- 1981

SOCIETY MEMBERSHIPS:

1989 - 1991 American Medical Association
1990 - present Member, American College of Physicians
1991 - 1993 Bexar County Medical Society
1991 - 1994 Society of General Internal Medicine

PRESENTATIONS:

1989 - 1990 Medical Jeopardy, a monthly housestaff quiz designed for board review.

1989 Resident Teaching Conference
"Blood Cultures and Bacteremia," an extensive review of the clinical and microbiological implications of bacteremia.

1990 Resident Teaching Conference
"Ehrlichiosis -- a new tick borne disease." A review of the epidemiology, symptoms, diagnosis and treatment."

1991 "The Clinical Significance of β -lactamases"
Presented to the Brewster/Pecos County Medical Society

1991 "The Role of ACE Inhibitors in the Treatment of Hypertension," Merck-Sharpe and Dohme

1992 "Clinical Pharmacy: A Physician's Perspective"
Central Texas Society of Hospital Pharmacists

PERSONAL ACHIEVEMENTS:

1980 State Champion
Texas State Championship Enduro Circuit
(endurance motorcycle racing)

PERSONAL INTERESTS:

Family, woodworking, personal computers

CLINICAL RESEARCH EXPERIENCE AS A PRINCIPLE INVESTIGATOR:

1998-1999 "Assessment of Algorithm for Adjunctive Treatment with (study drug) for Weight Loss in Obese Patients in a Large 16-Week, Multicenter, Open-Label Trial in Physician Practice Settings"

1998-1999 A Study of the Antiproteinuric Effects of (study drug) and Amlodipine in Type II Diabetes with Hypertension and Microalbuminuria or Overt Neuropathy

CLINICAL RESEARCH EXPERIENCE AS A SUB-INVESTIGATOR:

2005 – present, A 12-Week, Multicenter, Double-Blind, Randomized Efficacy and Safety Study of “Study Drug” for the Treatment of Constipation-Predominant Irritable Bowel Syndrome

2004-2005, A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Tramadol HCL/Acetaminophen for the Treatment of Painful Diabetic Neuropathy (Protocol CAPSS-237)

2004-2005, A 24-Week Randomized, Double-blind, Double-dummy, Multicenter Study to Compare the Efficacy of (study drug) and (study drug) in Subjects with Type 2 Diabetes Mellitus

2003-2004, A Phase 3, Randomized, Double-Blind, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of an Investigational Drug in Combination with Metformin Compared to Pioglitazone in Combination with Metformin in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

2002-2002 Phase IIIb, A Prospective, Randomized, Double-Blind, Parallel-Group, Study Comparing the Antiproteinuric Effects of (study drug) and (study drug) When Each are Added to Losarta 100mg in Treating Diabetic Hypertensive Subjects with Proteinuria

2002-2002 Phase III, A Randomized, Double-Blind, Safety, and Efficacy Pilot Study of (study drug) Versus (study drug) as First-Line Antihypertensive Therapy in Patients With Type II Diabetes Mellitus and Hypertension

2002-2002 Phase III, A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of an Investigational Study Drug in Subjects with Type II Diabetes

2002-2002 Phase III, A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of (study drug) Over 12 Weeks Followed by a 4-week Re-randomized Treatment Period in Diarrhea-Predominant Irritable Bowel Syndrome Subjects

2001-2002 Phase III, “An Open-label, Multinational, Multicenter, Extension Trial to Assess the Long-term Safety and Efficacy of (study drug) in Subjects in the ZD4522 Clinical Trial Program

2001—2002 Phase III, Randomized, Open-Label, Multicenter Trial of the Safety and Effectiveness of (study drug) and Amoxicillin/Clavulanic Acid (Augmentin®) in Outpatients with Respiratory Tract Infections in Usual Care Settings.

2001—2002 Phase IV, An Open-Label, Multicenter, Single Group Study to Assess the Bacteriological Eradication, Clinical Efficacy and Safety of (study drug) Given Once Daily for Five Days in the Treatment of Acute Bacterial Sinusitis (ABS)

2001—2002 Phase III, A Multicenter, Double-Blind, Randomized, Placebo-and Active-Controlled, Parallel Study to Evaluate the Lipid Altering Efficacy and Safety of (study drug) in Patients with Metabolic Syndrome and Dyslipidemia

2001—2002 Phase IV, A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Flexible Dose Study to Evaluate the Efficacy and Safety of (study drug) in Males with Erectile Dysfunction and Congestive Heart Failure

2001—2002 Phase IV, A Randomized, Open Label 16 – Week Study Comparing Breakthrough Bleeding Profiles of Women on Femhrt® 1/5 Or Prempro™

2001—2002 Phase III, A Double-Blind Placebo-Controlled, Parallel Group Design Study of Two Doses of (study drug) vs. Placebo for the Treatment of Sexual Dysfunction (Hypoactive Desire) in Postmenopausal Women

2001—2002 Phase III, Study of the efficacy and tolerability of (study drug) and twice daily naproxen vs. placebo in the treatment of Hispanic subjects with osteoarthritis of the knee

2001—2002 Phase III, A multicenter, eight-week treatment, single step titration, open-label study assessing the percentage of dyslipidemic patients achieving LDL cholesterol target with (study drug) starting doses of 10 mg, 20 mg, 40 mg, and 80mg

2001—2002 Phase III, Long-Term, Open-Label, Safety and Tolerability Study of (study drug) in Subjects with Primary Hypercholesterolemia

2001—2002 Phase III, Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril

2001—2001 Phase III, “A Double-Blind Randomized Study to Evaluate the Effects of Fixed Combination Metformin/Glipizide Therapy in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Half-Maximum to Maximum of the Labeled Doses of Sulfonylurea Monotherapy

2000—2002 A Phase IV, Randomized, Placebo-Controlled, Parallel Group (with Subject Option for the Treatment Switch), Double-Blind Study with Open Label Treatment to Evaluate the Efficacy and Safety of (study drug) in Hispanic Americans with Erectile Dysfunction.

2000—2002 A Phase III, Multicenter, Randomized, Double-Blind, Parallel Group Trial Comparing the Safety and Efficacy of (study drug) to (study drug) as First Line Therapy in Patients with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control with Diet and Exercise.

2000—2002 A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of (study drug) Added on to a Background of (study drug) Tablets in /subjects with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control on (study drug) Therapy.

2000—2001 A Phase III, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of (study drug) versus Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy.

2000—2002 A Phase III, Randomized, Placebo Controlled, Double Blinded Trial of (study drug) to Repair Hypokalemia and Maintain Serum Potassium in Hypertensive Patients Treated with Diuretic.

2000—2001 A Phase III, “A Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of (study drug) and Enalapril in the Treatment of Subjects with Hypertension”.

2000—2000 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel, 9 Week Dose Ranging Study of (study drug) in the Treatment of Mild to Moderate Hypertension

2000—2000 A Phase III, Twenty-Four Week Randomized, Open Label Study of Health Care Resource Use, Quality of Life and Productivity with (study drug) 1mg Twice Daily Versus Traditional Therapy in Females with Irritable Bowel Syndrome Whose Predominant Bowel Symptom is Diarrhea.

1999-2002 John A. Hartford Foundation Depression Initiative: IMPACT Study (in seniors)

1999-2002 A Phase III, Double-Blind Efficacy and Safety Study of One Dose of (study drug) (10 mg) Compared to Placebo in Subjects with Primary Hypercholesterolemia

1999-2002 A 24-Week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of (study drug) and Atorvastatin in the Treatment of Subjects With Hypercholesterolemia and Documented Atherosclerosis

1999—2000 A Twenty-Four Week, Randomized, Double-Blind Study of the Effects of (study drug) Versus Trental® (Pentoxifylline) and Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease

1999—2000 A Phase III, Randomized, Double-Blind, Active Control Trial to Evaluate the Safety and Efficacy of a Fixed Combination (study drug) Product in Patients with Type II Diabetes Mellitus Who Have Inadequate Glycemic Control on Maximum Dose Sulfonylurea Monotherapy

1999—1999 A Randomized, Double-Blind, Amlodipine and Losartan-Controlled Study of (study drug) in Subjects with Mild to Moderate Hypertension

1998-2002 Double-Blind, Randomized, Placebo-Controlled Study of (study drug) as Prevention of Cerebrovascular Events in Patients with a Previous Transient Ischemic Attack (TIA) or Stroke”

1998-1999 “A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of (study drug) Administered Once or Twice a Day in Patients with Type 2 Diabetes Who have Inadequate Glycemic Control with Diet and Exercise”

1998-1999 “The Efficacy and Safety of (study drug) Added to Hydrochlorothiazide for the Treatment of Hypertension in Subjects Non-Responsive to Hydrochlorothiazide Alone“

1998-1999 “A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Elective Titration Study of (study drug) in the Treatment of Mild to Moderate Hypertension”

1998-1999 “A Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of (study drug) and Enalapril in the Treatment of Subjects with Severe Hypertension”

1998 “A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Dose Response Study of the Safety, Pharmacokinetics and Effect on Pain and Function of (study drug) in Subjects with Osteoarthritis of the Knee”

1998 “CONVINCE Protocol for Mild Hypertension”

PROFESSIONAL REFERENCES:

Andy Diehl M.D.
Professor of Medicine
Chief—General Internal Medicine
Department of Internal Medicine
University of Texas Health Science Center at San Antonio
San Antonio, TX 78248

Jay Peters M.D.
Associate Professor of Medicine
Department of Internal Medicine
University of Texas Health Science Center at San Antonio
San Antonio, TX 78248

Gary Harris M.D.
Associate Professor of Medicine
Department of Internal Medicine
University of Texas Health Science Center at San Antonio
San Antonio, TX 78248